Skip to main content
Erschienen in: Diabetologia 6/2010

01.06.2010 | Article

Oligodeoxynucleotide IMT504 induces a marked recovery in a streptozotocin-induced model of diabetes in rats: correlation with an early increase in the expression of nestin and neurogenin 3 progenitor cell markers

verfasst von: M. S. Bianchi, A. Hernando-Insúa, N. A. Chasseing, J. M. Rodríguez, F. Elías, N. Lago, J. Zorzopulos, C. Libertun, A. D. Montaner, V. A. Lux-Lantos

Erschienen in: Diabetologia | Ausgabe 6/2010

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

IMT504 is an oligonucleotide that promotes tissue repair in bone injury and neuropathic pain models by stimulating progenitor cells. Here we evaluated the effect of IMT504 on the recovery of islet function in a streptozotocin (STZ)-induced model of diabetes in the rat.

Methods

Male Sprague–Dawley rats were injected with STZ (60 mg/kg, i.p., day 1) or citrate buffer (Control). Animals with glycaemia between 11 and 20 mmol/l on day 4 were injected with IMT504 (4 mg/animal in saline, s.c., STZ-IMT504) or with saline (STZ-Saline) for 10 days. Glycaemia and water and food intake were recorded for 33 days. Intraperitoneal glucose tolerance tests (IPGTTs) were performed on day 30. On day 35, overnight-fasted animals were killed and blood samples and pancreases collected for hormonal and histological studies. A second group of STZ-IMT504 rats was killed, together with Control and STZ-Saline rats, after two consecutive days of blood glucose decreases after the beginning of IMT504 treatment. Pancreases were collected and proliferating cell nuclear antigen (PCNA), nestin and neurogenin 3 (NGN3) detected by immunohistochemistry.

Results

IMT504 greatly improved blood glucose and food and water intakes in STZ-IMT504 rats by day 8, as well as IPGTTs on day 30. Significant increases in islet number and beta cell content were observed in STZ-IMT504 rats (day 33). Furthermore, after two to five IMT504 injections, blood glucose decreased, and an increase in pancreatic nestin (mainly in endothelial cells), PCNA and NGN3 production (in islets) was observed in STZ-IMT504 rats.

Conclusions/interpretation

IMT504 induced a marked recovery of STZ-induced diabetes that correlated with early production of progenitor cell markers, such as nestin and NGN3.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Nikoopour E, Schwartz JA, Singh B (2008) Therapeutic benefits of regulating inflammation in autoimmunity. Inflamm Allergy Drug Targets 7:203–210CrossRefPubMed Nikoopour E, Schwartz JA, Singh B (2008) Therapeutic benefits of regulating inflammation in autoimmunity. Inflamm Allergy Drug Targets 7:203–210CrossRefPubMed
2.
Zurück zum Zitat Fallarino F, Volpi C, Zelante T et al (2009) IDO mediates TLR9-driven protection from experimental autoimmune diabetes. J Immunol 183:6303–6312CrossRefPubMed Fallarino F, Volpi C, Zelante T et al (2009) IDO mediates TLR9-driven protection from experimental autoimmune diabetes. J Immunol 183:6303–6312CrossRefPubMed
3.
Zurück zum Zitat Elias F, Flo J, Lopez RA, Zorzopulos J, Montaner A, Rodriguez JM (2003) Strong cytosine–guanosine-independent immunostimulation in humans and other primates by synthetic oligodeoxynucleotides with PyNTTTTGT motifs. J Immunol 171:3697–3704PubMed Elias F, Flo J, Lopez RA, Zorzopulos J, Montaner A, Rodriguez JM (2003) Strong cytosine–guanosine-independent immunostimulation in humans and other primates by synthetic oligodeoxynucleotides with PyNTTTTGT motifs. J Immunol 171:3697–3704PubMed
4.
Zurück zum Zitat Krieg AM, Yi AK, Matson S et al (1995) CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546–549CrossRefPubMed Krieg AM, Yi AK, Matson S et al (1995) CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546–549CrossRefPubMed
5.
Zurück zum Zitat Hernando IA, Montaner AD, Rodriguez JM et al (2007) IMT504, the prototype of the immunostimulatory oligonucleotides of the PyNTTTTGT class, increases the number of progenitors of mesenchymal stem cells both in vitro and in vivo: potential use in tissue repair therapy. Stem Cells 25:1047–1054CrossRef Hernando IA, Montaner AD, Rodriguez JM et al (2007) IMT504, the prototype of the immunostimulatory oligonucleotides of the PyNTTTTGT class, increases the number of progenitors of mesenchymal stem cells both in vitro and in vivo: potential use in tissue repair therapy. Stem Cells 25:1047–1054CrossRef
6.
Zurück zum Zitat Su SC, Pei D, Hsieh CH, Hsiao FC, Wu CZ, Hung YJ (2010) Circulating pro-inflammatory cytokines and adiponectin in young men with type 2 diabetes. Acta Diabetol. doi:10.1007/s00592-009-0171-y Su SC, Pei D, Hsieh CH, Hsiao FC, Wu CZ, Hung YJ (2010) Circulating pro-inflammatory cytokines and adiponectin in young men with type 2 diabetes. Acta Diabetol. doi:10.​1007/​s00592-009-0171-y
7.
Zurück zum Zitat Crisan M, Yap S, Casteilla L et al (2008) A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 3:301–313CrossRefPubMed Crisan M, Yap S, Casteilla L et al (2008) A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 3:301–313CrossRefPubMed
8.
Zurück zum Zitat Lardon J, Rooman I, Bouwens L (2002) Nestin expression in pancreatic stellate cells and angiogenic endothelial cells. Histochem Cell Biol 117:535–540CrossRefPubMed Lardon J, Rooman I, Bouwens L (2002) Nestin expression in pancreatic stellate cells and angiogenic endothelial cells. Histochem Cell Biol 117:535–540CrossRefPubMed
9.
Zurück zum Zitat Xu X, D'Hoker J, Stange G et al (2008) Beta cells can be generated from endogenous progenitors in injured adult mouse pancreas. Cell 132:197–207CrossRefPubMed Xu X, D'Hoker J, Stange G et al (2008) Beta cells can be generated from endogenous progenitors in injured adult mouse pancreas. Cell 132:197–207CrossRefPubMed
10.
Zurück zum Zitat Gao X, Song L, Shen K, Wang H, Niu W, Qin X (2008) Transplantation of bone marrow derived cells promotes pancreatic islet repair in diabetic mice. Biochem Biophys Res Commun 371:132–137CrossRefPubMed Gao X, Song L, Shen K, Wang H, Niu W, Qin X (2008) Transplantation of bone marrow derived cells promotes pancreatic islet repair in diabetic mice. Biochem Biophys Res Commun 371:132–137CrossRefPubMed
11.
Zurück zum Zitat Hanley NA, Hanley KP, Miettinen PJ, Otonkoski T (2008) Weighing up beta-cell mass in mice and humans: self-renewal, progenitors or stem cells? Mol Cell Endocrinol 288:79–85CrossRefPubMed Hanley NA, Hanley KP, Miettinen PJ, Otonkoski T (2008) Weighing up beta-cell mass in mice and humans: self-renewal, progenitors or stem cells? Mol Cell Endocrinol 288:79–85CrossRefPubMed
Metadaten
Titel
Oligodeoxynucleotide IMT504 induces a marked recovery in a streptozotocin-induced model of diabetes in rats: correlation with an early increase in the expression of nestin and neurogenin 3 progenitor cell markers
verfasst von
M. S. Bianchi
A. Hernando-Insúa
N. A. Chasseing
J. M. Rodríguez
F. Elías
N. Lago
J. Zorzopulos
C. Libertun
A. D. Montaner
V. A. Lux-Lantos
Publikationsdatum
01.06.2010
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 6/2010
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-010-1694-z

Weitere Artikel der Ausgabe 6/2010

Diabetologia 6/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

NSCLC: Progressionsfreies Überleben unter Osimertinib fast versiebenfacht

06.06.2024 ASCO 2024 Kongressbericht

Erste Ergebnisse der Phase-III-Studie LAURA etablieren Osimertinib als neuen Therapiestandard für Menschen mit nicht-resezierbarem, EGFR-mutiertem, nicht-kleinzelligem Lungenkarzinom im Stadium III, die nach definitiver Radiochemotherapie progressionsfrei sind. Auf der ASCO-Tagung wurden diese beeindruckenden Ergebnisse besprochen.

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gute molekulare Response, aber seltener ernste Nebenwirkungen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.